Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements

Jan 01 2011

• By Bridget Silverman

Related Content

When Hard Data Are Sparse, FDA Looks To The Experts

Sep 01 2010

Context Is Key To Accelerated Approval In Oncology, Arzerra Review Shows

Sep 01 2010

Acorda's Novel Primary Endpoint For Ampyra Was Made Possible By A Supporting Scaffolding Of Secondary Analyses

Apr 01 2010

HRA’s Efficient <i>Ella</i> Development Strategy Begat FDA’s Efficient NDA Review

Nov 01 2010

REMS 2.0: FDA Refining New Drug Safety Tools

Nov 01 2010

FDA's Victoza Decision BalancedUnknown Cancer Risk Against Known FDAAA Measures

Feb 01 2010

Provenge Panel's Uncertainty Was More Persuasive To FDA Than Its Vote

Jun 01 2010

Zortress Approval Delay Caused By Novartis Attempts To Avoid Controlled Trial Of Dosing Regimen

Oct 01 2010

FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty

Dec 13 2010

FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS

Jan 01 2010

Score One For FDAAA: Uloric Approval Was Clinched By Post-Market Powers

Jul 01 2010

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window